Haowen Zhong, Ya Liu, Zhenjian Xu, Peifeng Liang, Hui Yang, Xiao Zhang, Jun Zhao, Junzhen Chen, Sha Fu, Ying Tang, Jun Lv, Julie Wang, Nancy Olsen, Anping Xu, Song Guo Zheng
Abstract
Lupus nephritis is one of most severe complications of systemic erythematosus lupus and current approaches are not curative for lupus nephritis. Although CD4+Foxp3+regulatory T cells (Treg) are crucial for prevention of autoimmunity, the therapeutic effect of these cells on lupus nephritis is not satisfactory. We previously reported that CD8+CD103+Treg inducedex vivowith TGF-β1 and IL-2 (CD8+CD103+iTreg), regardless of Foxp3 expression, displayed potent immunosuppressive effect on Th cell response and had therapeutic effect on Th cell-mediated colitis. Here, we tested whether CD8+CD103+iTreg can ameliorate lupus nephritis and determined potential molecular mechanisms. Adoptive transfer of CD8+CD103+iTreg but not control cells to chronic graft-versus-host disease with a typical lupus syndrome showed decreased levels of autoantibodies and proteinuria, reduced renal pathological lesions, lowered renal deposition of IgG/C3, and improved survival. CD8+CD103+iTreg cells suppressed not only T helper cells but also B cell responses directly that may involve in both TGF-β and IL-10 signals. Using RNA-seq, we demonstrated CD8+CD103+iTreg have its own unique expression profiles of transcription factors. Thus, current study has identified and extended the target cells of CD8+CD103+iTreg and provided a possible application of this new iTreg subset on lupus nephritis and other autoimmune diseases.
Pharmacology, Toxicology and Pharmaceutical Science
2
6%
Agricultural and Biological Sciences
2
6%
Unspecified
1
3%
Other
2
6%
Unknown
16
46%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2018.
All research outputs
#15,353,677
of 26,243,859 outputs
Outputs from Frontiers in immunology
#13,516
of 32,885 outputs
Outputs of similar age
#233,068
of 454,619 outputs
Outputs of similar age from Frontiers in immunology
#342
of 636 outputs
Altmetric has tracked 26,243,859 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 32,885 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,619 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 636 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
